目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key secondary sources
2.2.1.2 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 MARKET SHARE ASSESSMENT
2.6 RESEARCH ASSUMPTIONS
2.6.1 PARAMETRIC ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
4.2 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
4.3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
4.4 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
4.5 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
4.6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
4.7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer
5.2.1.2 Increasing focus on decentralized diagnostics and subsequent rise in R&D funding
5.2.1.3 Growing awareness associated with early disease diagnosis
5.2.1.4 Increasing use of POC diagnostic tests
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursements
5.2.2.2 High capital investments and low cost-benefit ratio
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory guidelines that impact product commercialization
5.2.4.2 Introduction of alternative technologies
5.3 PRICING ANALYSIS
5.3.1 AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, 2023-2025
5.3.2 AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC ASSAYS & KITS, BY KEY PLAYER, 2023-2025
5.3.3 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023-2025
5.4 PATENT ANALYSIS
5.4.1 LIST OF KEY PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
5.7.2 IMPORT DATA (HS CODE 3822)
5.7.3 EXPORT DATA (HS CODE 3822)
5.8 ECOSYSTEM ANALYSIS
5.8.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.9 PORTER'S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 BARGAINING POWER OF SUPPLIERS
5.9.3 THREAT OF SUBSTITUTES
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY FRAMEWORK
5.10.1.1 North America
5.10.1.1.1 US
5.10.1.1.2 Canada
5.10.1.2 EUROPE
5.10.1.2.1 Germany
5.10.1.2.2 UK
5.10.1.2.3 France
5.10.1.2.4 Italy
5.10.1.3 Asia Pacific
5.10.1.3.1 China
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.4.1 Brazil
5.10.1.4.2 Mexico
5.10.1.5 Middle East
5.10.1.5.1 Africa
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGIES
5.11.1.1 RT-PCR
5.11.2 COMPLEMENTARY TECHNOLOGIES
5.11.2.1 INAAT (Isolated Nucleic Acid Amplification Technology)
5.11.3 ADJACENT TECHNOLOGIES
5.11.3.1 CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 INVESTMENT & FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1: RAPID POINT OF CARE PCR TESTING STREAMLINES EMERGENCY CARE FOR HOSPITAL IN GERMANY
5.16.2 CASE STUDY 2: IMPLEMENTATION OF RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT
5.16.3 CASE STUDY 3: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION
5.17 IMPACT OF AI/GENERATIVE AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
5.17.1 INTRODUCTION
5.17.2 MARKET POTENTIAL OF AI
5.17.3 AI-USE CASES
5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE
5.17.5 FUTURE OF AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
5.18 TRUMP TARIFF IMPACT ON POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON COUNTRY/REGION
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Physicians' Offices/Clinics
5.18.5.2 Hospitals
5.18.5.3 Research Institutes

6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 ASSAYS & KITS
6.2.1 RECURRENT PURCHASE TO PROPEL MARKET
6.3 INSTRUMENTS & ANALYZERS
6.3.1 INCREASING ADOPTION OF ADVANCED POC TECHNOLOGIES TO DRIVE MARKET
6.4 SOFTWARE & SERVICES
6.4.1 UTILIZATION OF SOLUTIONS FOR ENHANCED USER EXPERIENCE TO SUPPORT MARKET GROWTH

7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 RT-PCR
7.2.1 HIGH SENSITIVITY AND SPECIFICITY TO BOOST DEMAND
7.3 INAAT
7.3.1 COST-BENEFITS AND RAPID AMPLIFICATION ABILITIES TO PROPEL MARKET
7.4 OTHER TECHNOLOGIES

8 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE
8.1 INTRODUCTION
8.2 BLOOD SAMPLES
8.2.1 ABILITY TO SUPPORT RAPID DETECTION FOR SEVERAL DISEASES TO PROPEL MARKET
8.3 URINE SAMPLES
8.3.1 NON-INVASIVE NATURE AND DETECTION OF LOW BIOMARKER CONCENTRATION TO BOOST DEMAND
8.4 OTHER SAMPLE TYPES

9 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 RESPIRATORY DISEASES
9.2.1 RISING INCIDENCE OF INFLUENZA AND RSV TO DRIVE MARKET
9.3 SEXUALLY TRANSMITTED DISEASES
9.3.1 RISING PREVALENCE OF HPV AND HIV TO DRIVE MARKET
9.4 HOSPITAL-ACQUIRED INFECTIONS
9.4.1 GROWING FOCUS ON TARGETED CLINICAL THERAPY FOR REDUCTION IN HAIS TO FUEL MARKET
9.5 CANCER
9.5.1 INCREASING PREFERENCE FOR ONCOLOGY THERAPEUTICS TO DRIVE MARKET
9.6 HEPATITIS
9.6.1 INCREASING PREVALENCE AMONG HIGH-RISK SUBGROUP POPULATIONS TO PROPEL MARKET
9.7 GASTROINTESTINAL DISORDERS
9.7.1 RISING INCIDENCE OF IBS TO SUPPORT MARKET GROWTH
9.8 OTHER APPLICATIONS

10 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS
10.2.1 CAPABILITY TO PURCHASE ADVANCED DIAGNOSTIC EQUIPMENT AND ABILITY TO SUPPORT HIGH PATIENT FOOTFALL TO PROPEL MARKET
10.2.1.1 Sepsis
10.2.1.1.1 Rising requirement for rapid diagnosis & treatment to fuel uptake
10.2.1.2 Gastroenteritis
10.2.1.2.1 Increasing admissions to critical care units and rising focus on molecular tools for diagnosis to fuel uptake
10.2.1.3 Meningoencephalitis
10.2.1.3.1 Initialization of targeted treatment due to high mortality risk to fuel market
10.2.1.4 Other diseases
10.3 PHYSICIANS' OFFICES/CLINICS
10.3.1 RAPID RESULTS AND INDIVIDUALIZED CARE TO FUEL MARKET
10.4 RESEARCH INSTITUTES
10.4.1 INCREASING FOCUS ON GENOMICS & PROTEOMICS RESEARCH TO BOOST DEMAND
10.5 OTHER END USERS

11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
11.2.2 US
11.2.2.1 High healthcare expenditure for advanced molecular diagnostic technologies to drive market
11.2.3 CANADA
11.2.3.1 Favorable government initiatives for early disease diagnosis awareness to fuel market
11.3 EUROPE
11.3.1 EUROPE: MACROECONOMIC OUTLOOK
11.3.2 GERMANY
11.3.2.1 Universal healthcare coverage and favorable growth for decentralized care settings to fuel market
11.3.3 UK
11.3.3.1 Rising prevalence of STIs to boost demand
11.3.4 FRANCE
11.3.4.1 High disease burden of infectious diseases and cancer to drive market
11.3.5 ITALY
11.3.5.1 Rising demand for high-precision diagnostic tools to support market growth
11.3.6 SPAIN
11.3.6.1 Rising incidence of respiratory illnesses and HIV to boost demand
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
11.4.2 CHINA
11.4.2.1 Increasing incidence of influenza and epidemics to propel market
11.4.3 JAPAN
11.4.3.1 Growing access to advanced & affordable healthcare services to fuel market
11.4.4 INDIA
11.4.4.1 Expanding healthcare access and increasing prevalence of HIV to propel market
11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
11.5.2 BRAZIL
11.5.2.1 High incidence of hepatitis to support market uptake
11.5.3 MEXICO
11.5.3.1 Rising cases of TB and HAIs to fuel market
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
11.6.2 KINGDOM OF SAUDI ARABIA (KSA)
11.6.2.1 Improvements in healthcare infrastructure to drive market
11.6.3 UNITED ARAB EMIRATES (UAE)
11.6.3.1 Rising technological advancements in molecular diagnostics to fuel market
11.6.4 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
12.3 REVENUE SHARE ANALYSIS, 2022-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1 Company footprint
12.5.5.2 Region footprint
12.5.5.3 Product & service footprint
12.5.5.4 Technology footprint
12.5.5.5 Application footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1 Detailed list of key startups/SMEs
12.6.5.2 Competitive benchmarking of key emerging players/startups (1/2)
12.6.5.3 Competitive benchmarking of key startups/SMEs (2/2)
12.7 COMPANY VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
12.7.2 COMPANY VALUATION
12.8 BRAND/PRODUCT COMPARISON
12.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 DANAHER CORPORATION
13.1.1.1 Business overview
13.1.1.2 Products/Services offered
13.1.1.3 Recent developments
13.1.1.3.1 Product/Service launches & approvals
13.1.1.3.2 Deals
13.1.1.3.3 Expansions
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 BIOMERIEUX
13.1.2.1 Business overview
13.1.2.2 Products/Services offered
13.1.2.3 Recent developments
13.1.2.3.1 Product/Service launches & approvals
13.1.2.3.2 Deals
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 F. HOFFMANN-LA ROCHE LTD.
13.1.3.1 Business overview
13.1.3.2 Products/Services offered
13.1.3.3 Recent developments
13.1.3.3.1 Products/Services launches & approvals
13.1.3.3.2 Deals
13.1.3.3.3 Expansions
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses & competitive threats
13.1.4 ABBOTT
13.1.4.1 Business overview
13.1.4.2 Products/Services offered
13.1.4.3 Recent developments
13.1.4.3.1 Deals
13.1.4.4 MnM view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses & competitive threats
13.1.5 QIAGEN N.V.
13.1.5.1 Business overview
13.1.5.2 Products/Services offered
13.1.5.3 Recent developments
13.1.5.3.1 Product launches & approvals
13.1.5.3.2 Deals
13.1.5.3.3 Expansions
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses & competitive threats
13.1.6 QUIDELORTHO CORPORATION
13.1.6.1 Business overview
13.1.6.2 Products/Services offered
13.1.6.3 Recent developments
13.1.6.3.1 Product/Service launches & approvals
13.1.6.3.2 Deals
13.1.6.3.3 Expansions
13.1.7 CO-DIAGNOSTICS, INC.
13.1.7.1 Business overview
13.1.7.2 Products/Services offered
13.1.7.3 Recent developments
13.1.7.3.1 Deals
13.1.7.3.2 Expansions
13.1.8 BIOCARTIS
13.1.8.1 Business overview
13.1.8.2 Products/Services offered
13.1.8.3 Recent developments
13.1.8.3.1 Product/Service launches & approvals
13.1.8.3.2 Deals
13.1.9 SD BIOSENSOR, INC.
13.1.9.1 Business overview
13.1.9.2 Products/Services offered
13.1.9.3 Recent developments
13.1.9.3.1 Product/Service launches
13.1.9.3.2 Deals
13.1.9.3.3 Other developments
13.1.10 GENEDRIVE PLC
13.1.10.1 Business overview
13.1.10.2 Products/Services offered
13.2 OTHER PLAYERS
13.2.1 BINX HEALTH, INC.
13.2.2 MOLBIO DIAGNOSTICS LIMITED
13.2.3 OPGEN, INC.
13.2.4 GENOMADIX
13.2.5 VISBY MEDICAL, INC.
13.2.6 QUANTUMDX GROUP LTD.
13.2.7 DETECTACHEM
13.2.8 LABSYSTEMS DIAGNOSTICS OY
13.2.9 AKONNI BIOSYSTEMS, INC.
13.2.10 UBIQUITOME LIMITED
13.2.11 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.
13.2.12 NUCLEIN, LLC
13.2.13 GENES2ME
13.2.14 AXXIN
13.2.15 HUWEL LIFESCIENCES

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS